{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T21:09:21Z","timestamp":1760044161640,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1016\/j.jsat.2007.02.004","type":"journal-article","created":{"date-parts":[[2007,5,18]],"date-time":"2007-05-18T20:08:46Z","timestamp":1179518926000},"page":"147-156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Availability of addiction medications in private health plans"],"prefix":"10.1016","volume":"34","author":[{"given":"Constance M.","family":"Horgan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Reif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominic","family":"Hodgkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah W.","family":"Garnick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth L.","family":"Merrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2007.02.004_bib1","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1111\/j.1521-0391.2003.tb00496.x","article-title":"Current pharmacotherapies of alcoholism: A U.S. perspective","volume":"12","author":"Anton","year":"2003","journal-title":"American Journal on Addictions"},{"year":"1998","author":"Center for Substance Abuse Treatment","series-title":"Naltrexone and alcoholism treatment","key":"10.1016\/j.jsat.2007.02.004_bib2"},{"year":"2004","author":"Center for Substance Abuse Treatment","series-title":"Clinical guidelines for the use of buprenorphine in the treatment of opioid Addiction","key":"10.1016\/j.jsat.2007.02.004_bib3"},{"author":"Centers for Medicare and Medicaid Services","key":"10.1016\/j.jsat.2007.02.004_bib4"},{"key":"10.1016\/j.jsat.2007.02.004_bib5","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jsat.2004.06.005","article-title":"Consensus statement on office-based treatment of opioid dependence using buprenorphine","volume":"27","author":"Fiellin","year":"2004","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2007.02.004_bib6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1468-0009.2005.00347.x","article-title":"Mental health policy and psychotropic drugs","volume":"83","author":"Frank","year":"2005","journal-title":"Milbank Quarterly"},{"key":"10.1016\/j.jsat.2007.02.004_bib7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/ajhp\/61.1.81","article-title":"Examining the benefit of pharmacy benefit management companies","volume":"61","author":"Garis","year":"2004","journal-title":"American Journal of Health-System Pharmacy"},{"key":"10.1016\/j.jsat.2007.02.004_bib8","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1345\/aph.1E380","article-title":"Are incentive-based formularies inversely associated with drug utilization in managed care?","volume":"39","author":"Gleason","year":"2005","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1016\/j.jsat.2007.02.004_bib9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1300\/J069v23n04_02","article-title":"Naltrexone and pharmacy benefit management","volume":"23","author":"Harris","year":"2004","journal-title":"Journal of Addictive Diseases"},{"year":"2005","author":"Hoadley","series-title":"Cost containment strategies for prescription drugs: Assessing the evidence in the literature","key":"10.1016\/j.jsat.2007.02.004_bib10"},{"key":"10.1016\/j.jsat.2007.02.004_bib11","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.clinthera.2007.02.011","article-title":"Management of psychotropic medications in private health plans","volume":"29","author":"Hodgkin","year":"2007","journal-title":"Clinical Therapeutics"},{"unstructured":"Horgan, C. M., Garnick, D. W., Merrick, E. L., & Hodgkin, D. (in review) Changes in how health plans provide behavioral health services. Manuscript in preparation.","key":"10.1016\/j.jsat.2007.02.004_bib12"},{"key":"10.1016\/j.jsat.2007.02.004_bib13","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1377\/hlthaff.22.5.84","article-title":"Managing psychotropic drug costs: Will formularies work?","volume":"22","author":"Huskamp","year":"2003","journal-title":"Health Affairs"},{"author":"Kaiser Family Foundation","key":"10.1016\/j.jsat.2007.02.004_bib14"},{"key":"10.1016\/j.jsat.2007.02.004_bib15","first-page":"195","article-title":"The design of the community tracking study: A longitudinal study of health system change and its effects on people","volume":"33","author":"Kemper","year":"1996","journal-title":"Inquiry"},{"key":"10.1016\/j.jsat.2007.02.004_bib16","first-page":"621","article-title":"Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization","volume":"11","author":"Landsman","year":"2005","journal-title":"American Journal of Managed Care"},{"key":"10.1016\/j.jsat.2007.02.004_bib17","first-page":"154","article-title":"Are medications for alcoholism underutilized? An analysis of private-sector and Medicaid claims","volume":"16","author":"Mark","year":"2004","journal-title":"Drug Benefits Trends"},{"year":"2005","author":"Mark","series-title":"National expenditures for mental health services and substance abuse treatment 1991\u20132001 (no. SMA 05-3999)","key":"10.1016\/j.jsat.2007.02.004_bib18"},{"key":"10.1016\/j.jsat.2007.02.004_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001333.pub2","article-title":"Oral naltrexone maintenance treatment for opioid dependence","volume":"25","author":"Minozzi","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.jsat.2007.02.004_bib20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/00115677-200412020-00002","article-title":"Impact of three-tier pharmacy benefit structures on consumer attitudes, pharmacy, medical utilization and costs: A critical review","volume":"12","author":"Nair","year":"2004","journal-title":"Disease Management & Health Outcomes"},{"author":"National Institute of Alcohol Abuse and Alcoholism","key":"10.1016\/j.jsat.2007.02.004_bib21"},{"year":"2006","author":"National Institute of Drug Abuse","series-title":"Principles of effective treatment for criminal justice populations","key":"10.1016\/j.jsat.2007.02.004_bib22"},{"year":"2005","author":"National Quality Forum","series-title":"Evidence-based treatment practices for substance use disorders: Workshop proceedings","key":"10.1016\/j.jsat.2007.02.004_bib23"},{"key":"10.1016\/j.jsat.2007.02.004_bib24","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0149-2918(03)90035-X","article-title":"Approaches to pharmacy benefit management and the impact of consumer cost-sharing","volume":"25","author":"Olson","year":"2002","journal-title":"Clinical Therapeutics"},{"key":"10.1016\/j.jsat.2007.02.004_bib25","series-title":"Principles of addiction medicine","first-page":"751","article-title":"Opioid maintenance treatment","author":"Payte","year":"2003"},{"year":"2002","author":"Research Triangle Institute","series-title":"SUDAAN user's manual: Release 8.0","key":"10.1016\/j.jsat.2007.02.004_bib26"},{"key":"10.1016\/j.jsat.2007.02.004_bib27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.pharmthera.2005.06.014","article-title":"Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs","volume":"108","author":"Saxon","year":"2005","journal-title":"Pharmacology and Therapeutics"},{"author":"Substance Abuse and Mental Health Services Administration","key":"10.1016\/j.jsat.2007.02.004_bib28"},{"author":"Substance Abuse and Mental Health Services Administration","key":"10.1016\/j.jsat.2007.02.004_bib29"},{"key":"10.1016\/j.jsat.2007.02.004_bib30","article-title":"Buprenorphine: An alternative to methadone","volume":"45","author":"The Medical Letter","year":"2003","journal-title":"The Medical Letter on Drugs and Therapeutics"},{"key":"10.1016\/j.jsat.2007.02.004_bib31","article-title":"NIDA at 30: Committed to scientific solutions for drug addiction problems","volume":"19","author":"Volkow","year":"2004","journal-title":"NIDA Notes"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547207000608?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547207000608?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:32:28Z","timestamp":1760038348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547207000608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["S0740547207000608"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2007.02.004","relation":{},"ISSN":["0740-5472"],"issn-type":[{"type":"print","value":"0740-5472"}],"subject":[],"published":{"date-parts":[[2008,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Availability of addiction medications in private health plans","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2007.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}